I think this abstract is quite new, I have not seen it before, anyway. It is on the 1511 men, a followup or reanalysis, don't know. Shows that ICI failures can do well on muse - surprised me.
As far as I can see neither Engel nor Mcvary are authors of at least the early 1511 studies.
McVary is uro has good publications, author of macrochem sponsored study at AUA meeting.
nums.nwu.edu
(go to staff for McVary)
Engel is molecular biologist/geneticist/biochemist with excellent publciations
x.biochem.nwu.edu
(unless there are two JD Engels at Northwestern Uni)
What is he doing?
DaiS
TI: Transurethral alprostadil as therapy for patients who withdrew
from or failed prior intracavernous injection therapy
AU: Engel_JD, McVary_KT
NA: 303 E CHICAGO AVE,TARRY 11-175,CHICAGO,IL,60611
NORTHWESTERN UNIV,SCH MED,DEPT UROL,CHICAGO,IL,60611
JN: UROLOGY, 1998, Vol.51, No.5, pp.687-692
IS: 0090-4295
AB: Objectives. Patients experiencing erectile dysfunction who fail intracavernous injection (ICI) therapy are commonly believed to
have exhausted pharmacologic options. We evaluated the efficacy
and safety of transurethral alprostadil (MUSE) in patients
experiencing erectile dysfunction who underwent prior ICI
therapy (alprostadil, papaverine, phentolamine, or a
combination of these).
Methods. Of the 1511 patients enrolled in a multicenter trial
of transurethral alprostadil, 452 (30%) reported prior ICI
therapy and its effects. These patients tested up to four dose
levels of transurethral alprostadil in the clinic, and those
who achieved an erection satisfactory for intercourse were
treated at home in a double-blind, placebo-controlled trial.
Results. Prior ICI therapy was reported to be ''not effective''
by 95 of 452 patients (21%), ''sometimes effective'' by 119 of
452 (26%), and ''effective'' by 238 of 452 (55%). in patients
reporting ICI therapy as ''not effective,'' 58% achieved an
erection sufficient for intercourse following transurethral
alprostadil therapy in the clinic; 47% of these responsive
patients reported successful sexual intercourse after
transurethral alprostadil therapy during home treatment. For
patients reporting ICI therapy as ''sometimes effective'' or
''effective,'' 68% achieved an erection sufficient for
intercourse following transurethral alprostadil therapy in the
clinic setting and 67% of these responsive patients reported
successful intercourse following transurethral alprostadil
therapy at home. Few adverse effects were encountered. The most
common adverse effect was penile pain, which occurred with 7.8%
of administrations.
Conclusions. Transurethral alprostadil therapy is an effective
therapeutic option for patients with erectile dysfunction and
may even ''rescue'' some patients who have failed prior
intracavernous injection therapy. |
